Cholesterol Tests Market

On 13 March 2026 the American College of Cardiology and the American Heart Association published a new dyslipidemia guideline that tells clinicians to measure lipoprotein(a) at least once in every adult’s life, adds apolipoprotein B for patients with residual risk and recommends cholesterol screening for all children aged 9 to 11. For the cholesterol tests market, that single document added a new test to the routine adult work-up and widened the screening age at both ends. Douglas Insights values the cholesterol tests market at USD 3.84 billion in 2025 and expects USD 6.78 billion by 2035, a compound annual growth rate of 5.86%. The build is bottom-up: about 2.40 billion cholesterol and lipid tests run in 2025 at an average manufacturer revenue of USD 1.60 per test, across laboratory reagents, point-of-care cartridges and home test strips. Test volume grows 4.6% a year as screening widens in Asia and guideline-driven testing rises, and revenue per test rises 1.2% a year as Lp(a) and apoB assays, priced several times above a standard panel, take share. This study sits within our in-vitro diagnostics coverage and follows the published Douglas Insights methodology.

Which lipid assays, cartridges and home kits count as cholesterol tests?

The cholesterol tests market covers the in vitro diagnostic products used to measure blood lipids: reagents and calibrators for the standard lipid panel of total cholesterol, HDL cholesterol, triglycerides and calculated or direct LDL cholesterol; direct LDL cholesterol assays; lipoprotein(a) assays; apolipoprotein B and advanced lipoprotein tests; point-of-care lipid analysers and their cartridges; and home and pharmacy self-test strips and meters. Cholesterol tests are counted at the manufacturer’s selling price per test, so laboratory service fees, physician fees, the general clinical chemistry analysers that also run many other tests and genetic tests for familial hypercholesterolaemia are excluded. A lipid panel counts as one test whether it reports four analytes or five. The Clinical Lab Automation Market report sizes the laboratory systems on which most cholesterol tests are run, and heart-health supplements bought after an abnormal result are sized in the Nutraceutical Products Market report.

Who gets cholesterol tests, and how often?

Cholesterol tests are ordered for four groups of people, and Douglas Insights estimates that repeat monitoring of treated patients generates about 45% of the 2.40 billion tests run in 2025. The first group is adults screened for cardiovascular risk, typically every 4 to 6 years from age 20 or 40 depending on the country, which produces about 30% of volume. The second is patients on lipid-lowering therapy, who need a baseline panel, a check 4 to 12 weeks after starting or changing a drug and then one or two tests a year; with about 300 million treated people worldwide, this group produces the largest share. The third is people with diabetes, chronic kidney disease or high blood pressure, whose annual reviews include a lipid panel and who account for about 18% of volume. The fourth, growing fastest from a small base, is children and young adults screened for inherited high cholesterol: familial hypercholesterolaemia affects roughly 1 in 250 people, and the 2026 guideline’s recommendation to screen all children aged 9 to 11 could add about 4 million US tests a year once adopted. Each group buys different products. Screening and monitoring run mostly on laboratory panels, pharmacy and community programmes use point-of-care cartridges, and motivated consumers and remote-care services increasingly use home kits, which is why the cholesterol tests market grows faster than the number of people tested.

How do FDA, CLIA and EU IVDR rules decide which cholesterol tests can be sold?

Cholesterol tests are regulated as in vitro diagnostic devices, and three rule sets decide which tests can be sold and where. In the United States, most lipid tests are Class I or Class II devices cleared by the Food and Drug Administration, and point-of-care analysers such as Abbott’s Cholestech LDX and PTS Diagnostics’ CardioChek hold CLIA waivers that let pharmacies, clinics and workplace screening programmes run them without a certified laboratory. In the European Union, the In Vitro Diagnostic Regulation, Regulation (EU) 2017/746, replaced self-certification with notified-body review for most tests, and transition deadlines extended in 2024 run to 2027 to 2029 depending on risk class, which adds EUR 100,000 to EUR 500,000 of conformity cost per assay family and pushes smaller reagent makers out. Accuracy standards are the third layer: the CDC Lipid Standardization Program certifies that laboratory methods measure total cholesterol within 3% of the reference, and Lp(a) assays are moving from mass units in mg/dL to molar units in nmol/L because the size of the apolipoprotein(a) particle varies between people. The 13 March 2026 guideline set its high-risk Lp(a) threshold at 125 nmol/L or 50 mg/dL, which is why laboratories are switching to isoform-insensitive assays calibrated in nmol/L.

What drives cholesterol test volume after the 2026 Lp(a) guideline?

Guideline-driven testing is the first driver. The 13 March 2026 ACC/AHA guideline recommends Lp(a) measurement at least once in adulthood, apoB for patients with cardiovascular-kidney-metabolic syndrome or high triglycerides, and screening of all children aged 9 to 11, and it introduces the PREVENT-ASCVD risk calculator for adults aged 30 to 79. Douglas Insights estimates that full US adoption of once-in-life Lp(a) testing alone adds about 25 million tests over five years, and models Lp(a) tests growing 16.5% a year from USD 269 million in 2025.

Cardiovascular disease burden is the second driver. Heart disease and stroke remain the leading causes of death worldwide according to the WHO Global Health Estimates, and statin, ezetimibe, PCSK9 and bempedoic acid therapy each require a baseline lipid panel and follow-up tests at 4 to 12 weeks and then yearly. Douglas Insights counts roughly 300 million people on lipid-lowering drugs worldwide in 2025, each generating 1 to 3 cholesterol tests a year.

Screening expansion in Asia is the third driver. China, India and Southeast Asian countries are adding lipid testing to national health check-up programmes and diabetes care, and India’s national screening campaign for non-communicable diseases covers adults over 30. Douglas Insights models Asia Pacific cholesterol test volume growing about 6.8% a year, and Asia Pacific revenue growing 7.96% a year, the fastest of any region.

Decentralised testing is the fourth driver. Point-of-care lipid analysers in pharmacies and clinics return a full panel from a fingerstick in 5 to 8 minutes, and home self-test kits sold online let consumers check cholesterol without a clinic visit. Douglas Insights values point-of-care and home cholesterol tests at USD 1.11 billion in 2025, growing about 7.0% a year, faster than central laboratory reagents at about 5.3%.

New lipid-lowering drugs are the fifth driver. Inclisiran, given twice a year, oral PCSK9 inhibitors in late-stage development and Lp(a)-lowering drugs such as pelacarsen and olpasiran all require lipid tests to select patients and confirm response, and an approved Lp(a) therapy would make the test a prescribing gate rather than a risk marker. Douglas Insights estimates that each approved Lp(a)-lowering drug adds 8 million to 12 million Lp(a) tests a year worldwide within three years of launch, which the faster scenario applies.

What restrains cholesterol test revenue as standard panels commoditise?

Price pressure on standard panels is the first restraint on cholesterol test revenue. Standard lipid reagents are a commodity sold in large volumes on automated chemistry analysers, and China’s volume-based procurement for in vitro diagnostic reagents, extended across provinces since 2021, has cut tender prices for common chemistry assays by 40% to 70%. Douglas Insights holds standard panel revenue per test flat to slightly negative in China through 2030 for this reason, and models standard lipid panels growing only 3.7% a year worldwide.

Reimbursement limits are the second restraint. Public payers in the United States, Europe and Japan cap how often lipid panels are reimbursed for patients without disease, commonly once every five years for screening, and many insurers do not yet pay for Lp(a) testing, which slows the guideline’s effect on volume. Assay standardisation is the third: Lp(a) results differ by up to 20% between methods that are not calibrated in molar units, and some laboratories delay adding the test until they can offer an isoform-insensitive assay. Calculated LDL is the fourth: the Martin-Hopkins and Sampson equations estimate LDL cholesterol from the standard panel accurately enough for most patients, which limits growth in direct LDL assays to 4.6% a year.

Laboratory consolidation is a fifth restraint. Hospital networks and reference laboratory chains tender their chemistry menus as one contract every 5 to 7 years, so a reagent maker that loses the analyser placement loses the cholesterol tests with it, and consolidation of US and European laboratories into fewer, larger buyers has cut average reagent prices on renewal by 3% to 8%.

Which cholesterol test type, from standard panels to Lp(a), carries the value?

Standard lipid panels carry the most value in the cholesterol tests market, at 70% of 2025 sales, and Lp(a) tests grow fastest. Douglas Insights values the four test types as follows.

Standard lipid panels are worth USD 2.69 billion because every cardiovascular risk assessment, statin start and annual health check begins with total cholesterol, HDL, triglycerides and LDL.

Direct LDL cholesterol assays are worth USD 576 million, used when triglycerides are high or LDL is very low and the calculated value becomes unreliable.

ApoB and advanced lipoprotein tests are worth USD 307 million, and the 2026 guideline’s recommendation of apoB for residual-risk patients lifts their growth to 9.6% a year.

Lp(a) tests are worth USD 269 million, the smallest type today, and they grow 16.5% a year because a once-in-life test for every adult turns a specialist assay into a routine one.

Do central labs, pharmacies or homes run most cholesterol tests?

Central laboratories run 71% of cholesterol tests by value, USD 2.73 billion in 2025, on high-throughput chemistry analysers from Roche, Abbott, Siemens Healthineers and Beckman Coulter in hospital and reference laboratories such as Quest Diagnostics and Labcorp. Point-of-care testing in pharmacies, physician offices and community screening takes 19%, USD 730 million, and grows about 6.6% a year as pharmacists in the United States, the United Kingdom, Canada and Australia take on cardiovascular risk checks. Home and self-testing takes 10%, USD 384 million, and grows about 7.8% a year through online retail and direct-to-consumer blood test services that post fingerstick kits to a laboratory.

What price does a cholesterol test fetch in the lab, the pharmacy and the home?

Cholesterol tests are priced per test at the manufacturer, and Douglas Insights puts the 2025 average at USD 1.60 across all types and settings. Laboratory reagents for a standard lipid panel cost a hospital or reference laboratory USD 0.40 to USD 1.20 per panel in high-volume contracts, and far less under Chinese procurement tenders. A direct LDL assay adds USD 0.50 to USD 1.50, an apoB assay USD 1.50 to USD 4.00, and an Lp(a) assay USD 3.00 to USD 8.00 per test, which is why each point of share Lp(a) gains lifts the market’s average price. Point-of-care cartridges for a full lipid panel sell for USD 8 to USD 15 each, and home self-test strips and kits for USD 3 to USD 12 per test at manufacturer level. The shift in mix toward Lp(a), apoB and decentralised tests raises average revenue per test by about 1.2% a year even as standard panel prices fall in China and in tenders elsewhere. A laboratory running 1 million lipid panels a year therefore spends roughly USD 0.4 million to USD 1.2 million on reagents, and adding Lp(a) for one-fifth of those patients adds about USD 0.3 million to USD 1.6 million more.

Which region runs the most cholesterol tests, North America or Asia Pacific?

North America buys the most cholesterol tests, 34% of 2025 value or USD 1.31 billion. North America grows 4.7% a year to USD 2.07 billion in 2035, because the United States runs the most lipid panels per head, has the widest point-of-care pharmacy network and is the first market to absorb the 2026 guideline’s Lp(a) and apoB recommendations. Asia Pacific buys 30%, USD 1.15 billion, and grows fastest at 7.96% a year to USD 2.48 billion, as China and India screen more adults and diabetes care spreads, although procurement tenders hold down Chinese prices. Europe buys 27%, USD 1.04 billion, growing 4.4% a year, where Lp(a) testing was already recommended by European guidance and national screening such as the NHS Health Check keeps volumes steady. Latin America buys 5%, USD 192 million, growing 6.1% a year with Brazilian and Mexican private laboratory chains. The Middle East and Africa buy 4%, USD 154 million, and are the wildcard at 6.8% a year: Gulf states with some of the world’s highest rates of diabetes are funding national cardiovascular screening, while most of Africa still tests only in hospitals.

Which companies supply cholesterol tests, and who is best placed for Lp(a)?

Roche leads the cholesterol tests market with about 18% of 2025 value on Douglas Insights estimates, and the five largest suppliers hold about 55%. Roche, Abbott, Siemens Healthineers and Beckman Coulter, part of Danaher, sell lipid reagents for their own chemistry analysers, so they win cholesterol testing as part of whole-laboratory contracts rather than test by test. QuidelOrtho, Mindray and Snibe compete for mid-sized laboratories, and Mindray has gained share in China and emerging markets on price. Randox and Denka lead Lp(a) and specialist lipid assays that are calibrated in molar units, and Sekisui Medical pioneered direct LDL and HDL methods. In point-of-care testing, Abbott’s Cholestech LDX and Afinion and PTS Diagnostics’ CardioChek lead pharmacy and clinic use, while Sinocare, Roche’s Accutrend and a range of Chinese and Korean makers compete in home self-testing. The advantage in central laboratories rests on the analyser installed base; in point-of-care and home testing it rests on CLIA waivers, retail distribution and price per cartridge. Lp(a) is where the order is most likely to change: laboratories choosing an isoform-insensitive assay in nmol/L after the 13 March 2026 guideline are reopening a test that was previously sent out to specialist laboratories, which gives Randox, Denka and the analyser makers that license their methods a chance to win share from incumbents on the basis of calibration rather than price.

How far could cholesterol testing reach by 2035 if payers refuse to cover Lp(a)?

The base case carries 4.6% growth in tests and 1.2% growth in revenue per test for a 5.86% revenue CAGR and USD 6.78 billion in 2035. In the slower scenario, payers refuse to reimburse Lp(a) testing, Chinese procurement spreads to more regions and screening programmes stall, so the legs fall to 2.8% and minus 0.2% and the cholesterol tests market reaches about USD 4.96 billion. In the faster scenario, the 2026 guideline is adopted quickly in the United States and Europe, Lp(a) testing becomes routine and home testing grows through telehealth and pharmacy channels, lifting the legs to 6.2% and 2.4% and carrying the market to about USD 8.88 billion. Each 1-point change in test volume growth moves the 2035 figure by roughly USD 677 million. Published estimates for cholesterol testing run between 5% and 8% a year; the Douglas figure sits inside that band because falling standard panel prices offset fast growth in Lp(a) and decentralised testing.

Douglas Exclusive: the cholesterol tests guideline adoption tracker

The cholesterol tests guideline adoption tracker follows, by country, which guidelines recommend Lp(a), apoB and childhood lipid screening, whether public and private payers reimburse each test, which laboratories offer Lp(a) in nmol/L, and the test volumes each change adds. It converts the 13 March 2026 ACC/AHA guideline and its European and Asian counterparts into expected cholesterol test volumes by year, so a diagnostics maker, laboratory chain or investor can see where Lp(a) and apoB demand will arrive first. Douglas Insights updates the tracker as payers and guideline bodies change their positions.

Methodology and receipts: how do 2.40 billion tests add up to USD 3.84 billion?

Douglas Insights built the cholesterol tests model bottom-up from test volumes and revenue per test across 4 test types, 3 testing settings and 5 regions. Volumes were derived from adult populations, screening intervals, the number of people on lipid-lowering therapy, national health check programmes and laboratory test statistics; revenue per test was set by type and setting from contract prices, procurement tenders and point-of-care and retail price lists. Totals were reconciled against the clinical chemistry and point-of-care revenue disclosed by 8 listed diagnostics companies. The receipts are 2.40 billion tests times USD 1.60 per test for 2025, 4.6% volume growth and 1.2% price growth to 2035, and Lp(a) rising from 7% to about 18% of value.

Sources

1. American Heart Association ACC/AHA issue updated guideline for managing lipids, cholesterol (2026)
2. EUR-Lex, Publications Office of the European Union Regulation (EU) 2017/746 on in vitro diagnostic medical devices (2017)
3. World Health Organization Global Health Estimates: leading causes of death and disability (2025)
4. World Health Organization Noncommunicable diseases data (2025)